TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03676387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided
Description: Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation \[ETT OD=0.55\*(subglottic diameter)+1.16\] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes.
Study: NCT02323711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate
Description: If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
Study: NCT02969447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of 10 units of intra venous oxytocin after fetal expulsion
Study: NCT03699631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
Study: NCT04264455

Intervention type: DEVICE
Intervention: Biomonitor
Description: Patients receive a Biomonitor only
Study: NCT00891176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PrevenarTM
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
Study: NCT02501421

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tuberculosis vaccine
Description: Live recombinant influenza vectored tuberculosis vaccine
Study: NCT02501421

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer
Study: NCT04050384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baby GentleStick
Description: The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
Study: NCT04264455

Intervention type: DEVICE
Intervention: Life Vest
Description: Patients receive a Wearable Cardioverter-Defibrillator; a Biomonitor is implanted additionally

Intervention type: DEVICE
Intervention: Implantable Cardioverter-Defibrillator (ICD)
Description: Patients receive an Implantable Cardioverter-Defibrillator (ICD)
Study: NCT00891176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MeningitecTM
Description: Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
Study: NCT02587312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard nicotine content cigarettes
Study: NCT03243864

Intervention type: DRUG
Intervention: Ceftazidime-avibactam
Description: Patients will be started on 2.5 gm IV every 8 hours
Study: NCT03744390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Description: Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
Study: NCT04264455

Intervention type: DEVICE
Intervention: Implantable Cardioverter-Defibrillator (ICD)
Description: Patients receive an Implantable Cardioverter-Defibrillator (ICD)

Intervention type: DEVICE
Intervention: Implantable Cardioverter-Defibrillator (ICD)
Description: Patients receive an Implantable Cardioverter-Defibrillator (ICD)
Study: NCT01160952

Intervention type: DRUG
Group type: OTHER
Intervention: itraconazole
Description: the two groups are defined by different treatment duration
Study: NCT00152438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone (Prometrium®)
Description: 300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 identical placebo pills daily, no active ingredient.
Study: NCT01753076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanezumab
Description: Ozanezumab injection solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% sodium chloride) infusion
Study: NCT00891176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-CTM
Description: Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: InfanrixTM hexa
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: InfanrixTM hexa
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: InfanrixTM penta
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: InfanrixTM penta
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: InfanrixTM IPV/Hib
Description: Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
Study: NCT04468399

Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.

Intervention type: OTHER
Intervention: Interviews with service providers
Description: Clinicians and lay staff will be interviewed regarding the ART initiation process.
Study: NCT00891176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: InfanrixTM IPV/Hib
Description: Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: InfanrixTM IPV
Description: Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: InfanrixTM IPV
Description: Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
Study: NCT03173937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omidubicel (former CordIn)
Description: Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn (TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn (TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn (TM) Non-cultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi CliniMACS(R) CD34 Reagent System
Description: The CliniMACS CD34 Reagent System is a medical device system that is designed for the in vitro enrichment of CD34+ target cells from heterogeneous hematologic cell populations. The process of CD34+ cell selection results in simultaneous passive depletion of donor lymphocytes, potentially obviating the need for immunosuppressive drugs to prevent GVHD.
Study: NCT01373281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, dengue serotype 1, 2, 3, 4 virus
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Sodium chloride (NaCl) 0.9%
Description: 0.5 mL, Subcutaneous
Study: NCT03620396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: After the serum collection is done from the patient for the assessment of trefoil factor 3, Non surgical periodontal therapy is carried out.
Study: NCT03020784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02824159

Intervention type: OTHER
Intervention: Blood samples for pharmacokinetics exploration
Description: 6 blood sample at regular intervals

Intervention type: OTHER
Intervention: Imagery
Description: Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan

Intervention type: OTHER
Intervention: Quality of life scale
Description: Quality of life will be evaluated with questionaries 5 times during the study

Intervention type: OTHER
Intervention: Detection of adverse events
Description: The detection will be assessed using the AMA (assistance des malades ambulatoires) system

Intervention type: GENETIC
Intervention: Saliva samples
Description: Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)

Intervention type: GENETIC
Intervention: Blood sample
Description: A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)

Intervention type: OTHER
Intervention: Biological statement
Description: The following parameters will be assessed :~* Complete blood count~* Hemoglobin~* Hepatic enzymes~* Creatinine clearance~* Lactate dehydrogenase rate~* Total bilirubin rate~* Cluster of differentiation 4 T lymphocytes rate~* Total gamma-globulins rate

Intervention type: OTHER
Intervention: Clinical examination
Description: The clinical examination are composed by :~* Weigh, Height and body mass index measurement~* Clinical state of patient during examination~* Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~* Presence of B symptomatology~* Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)
Study: NCT03589651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB050465
Description: Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
Study: NCT01406028

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone calls
Description: Phone calls to offer emotional support
Study: NCT05356819

Intervention type: DEVICE
Group type: OTHER
Intervention: Smart Capnography™, Microstream®
Description: patients monitored by capnograph
Study: NCT02961179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased dairy product

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary counselling
Study: NCT02072213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GL2702 GLARS-NF1
Description: 0.4mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GL2702 GLARS-NF1
Description: 0.4mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omix Ocas
Description: 0.4mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omix Ocas
Description: 0.4mg once a day
Study: NCT02328989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pessary
Description: The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
Study: NCT03020784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06818883
Description: Treatment
Study: NCT01017939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide
Description: Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
Study: NCT00006473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT01303068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C urea breath test Kit
Description: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 13C urea breath test Kit
Description: 20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
Study: NCT04441593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)
Description: Videoconferencing intervention to reduce alcohol use and chronic pain interference and severity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Psychoeducation and Information about Treatment Resources
Study: NCT01370707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000\~1500mg/day, 24weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30001/CJ-30002
Description: 0.6/1500mg\~0.9/1500mg/day, 24weeks
Study: NCT02813252

Intervention type: GENETIC
Intervention: JCAR015
Description: No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study: NCT00815750

Intervention type: OTHER
Group type: OTHER
Intervention: Information Gathering
Description: An information gathering phase leading to development of a new decision aid.

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: To test the newly developed decision aid.
Study: NCT01964469

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: mobile & web-based action plan
Description: Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile & web-based action plan
Description: Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
Study: NCT00688519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U0267
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
Study: NCT02570191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 uG in 0.5 mL solution administered once weekly for 48 weeks
Study: NCT01834248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given SC and ID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC
Study: NCT02969954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-efficacy for diabetes management
Description: Participants at both sites will watch a 12 minute video featuring the digital stories on diabetes. Following the video, participants will engage in a brief facilitated discussion regarding motivations and barriers to diabetes management, led by a trained Spanish-speaking facilitator.
Study: NCT03463135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucopyranosyl Lipid A (GLA)
Description: Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)
Description: Pharmaceutical form:Solution Route of administration: Sublingual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)
Description: Pharmaceutical form:Solution Route of administration: Sublingual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for GLA
Description: Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for GLA
Description: Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SLIT PE
Description: Pharmaceutical form:Solution Route of administration: Sublingual
Study: NCT01915004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Bladder Training Video

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: Bladder Training Video
Study: NCT04144452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education Session
Description: The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise plus educational session
Description: Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.